Evidence map›Paper›PMID 19597184›Full record

ArticleBlood2009

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, Susana Ben-Neriah, Ryan Woods, Christian Steidl, Martin J S Dyer, Reiner Siebert, John Kuruvilla, Richard Klasa and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed, 1 pooled it
19.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed, 1 synthesis or guideline pooled it, 581 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Trial
  8. Trial
  9. Trial
  10. Article
  11. Aging and cancer: current understandings and future perspectives.Signal transduction and targeted therapy · 2026
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Nathalie A JohnsonDepartment of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada.
Kerry J Savage
Olga Ludkovski
Susana Ben-Neriah
Ryan Woods
Christian Steidl
Martin J S Dyer
Reiner Siebert
John Kuruvilla
Richard Klasa
Joseph M Connors
Randy D Gascoyne
Douglas E Horsman
Genomics (United Kingdom) · GBBC Cancer Agency · CAMedical Research Council · GBUniversity Hospital Schleswig-Holstein · DE

Funding

MOLECULAR CLASSIFICATION OF B-CELL LYMPHOMAU01CA084967 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHAN, WING C. · 1999 to 2004
$4.1M
Medical Research Council MC_U132670597NCI NIH HHS U01 CA084967NCI NIH HHS UO1-CA84967-1
6 · The paper itself

Abstract

BCL2 and MYC are oncogenes commonly deregulated in lymphomas. Concurrent BCL2 and MYC translocations (BCL2(+)/MYC(+)) were identified in 54 samples by karyotype and/or fluorescence in situ hybridization with the aim of correlating clinical and cytogenetic characteristics to overall survival. BCL2(+)/MYC(+) lymphomas were diagnosed as B-cell lymphoma unclassifiable (BCLU; n = 36) with features intermediate between Burkitt lymphoma and diffuse large B-cell lymphoma (DLBCL); DLBCL (n = 17), or follicular lymphoma (n = 1). Despite the presence of a t(14;18), 5 cases were BCL2 protein-negative. Nonimmunoglobulin gene/MYC (non-IG/MYC) translocations occurred in 24 of 54 cases (44%) and were highly associated with DLBCL morphology (P < .001). Over a median follow-up of 5.3 years, 6 patients remained in remission and 32 died within 6 months of the MYC(+) rearrangement, irrespective of whether MYC(+) occurred at diagnosis (31 of 54) or transformation (23 of 54; P = .53). A non-IG/MYC translocation partner, absent BCL2 protein expression and treatment with rituximab-based chemotherapy, were associated with a more favorable outcome, but a low International Prognostic Index score and DLBCL morphology were independent predictors of overall survival. A comprehensive cytogenetic analysis of BCL2 and MYC status on all aggressive lymphomas may identify a group of high-risk patients who may benefit from chemotherapeutic regimens that include rituximab and/or BCL2-targeted therapy.

Indexed as

Translocation, GeneticAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsBurkitt LymphomaChromosomes, Human, Pair 14Chromosomes, Human, Pair 18Databases, FactualDisease-Free SurvivalFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntineoplastic AgentsMYC protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycRituximab

Identifiers

PMID19597184
PMCPMC2745846
OpenAlexW2153944703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.